Kezar Life Sciences
136 hedge funds and large institutions have $188M invested in Kezar Life Sciences in 2023 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 51 increasing their positions, 39 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
0.09% more ownership
Funds ownership: 8.4% → 8.48% (+0.09%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
53% less capital invested
Capital invested by funds: $401M → $188M (-$213M)
Holders
136
Holding in Top 10
2
Calls
$2.91M
Puts
$2.36M
Top Buyers
| 1 | +$10.6M | |
| 2 | +$4.52M | |
| 3 | +$2.93M | |
| 4 |
O
OrbiMed
New York
|
+$2.75M |
| 5 |
Barclays
London,
United Kingdom
|
+$2.01M |
Top Sellers
| 1 | -$10.1M | |
| 2 | -$9.46M | |
| 3 | -$3.76M | |
| 4 |
TLP
Tri Locum Partners
New York
|
-$3.33M |
| 5 |
State Street
Boston,
Massachusetts
|
-$3.18M |